BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Li X, Liu X, Chen Y, Yang C, Tan C, Wang B, Sun Y, Zhang X, Gao Y, Ding J, Meng L. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer. Cancer Biol Med 2019;16:66-83. [PMID: 31119047 DOI: 10.20892/j.issn.2095-3941.2018.0361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, Zhang X, He QJ, Ding J, Meng LH. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer. Signal Transduct Target Ther 2019;4:49. [PMID: 31798976 DOI: 10.1038/s41392-019-0085-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J, Meng LH. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. Cancer Lett 2022;524:206-18. [PMID: 34688842 DOI: 10.1016/j.canlet.2021.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wang YX, Zhang X, Ma QY, Hu LD, Zhang X, Wang Y, Xu L, Yang CH, Tan C, Kong XY, Ding J, Meng LH. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis 2021;12:85. [PMID: 33446653 DOI: 10.1038/s41419-020-03370-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zhang J, Xu D, Zhou Y, Zhu Z, Yang X. Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC. Front Oncol 2021;11:676041. [PMID: 34395246 DOI: 10.3389/fonc.2021.676041] [Reference Citation Analysis]
5 Cayo A, Segovia R, Venturini W, Moore-Carrasco R, Valenzuela C, Brown N. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Int J Mol Sci 2021;22:8149. [PMID: 34360912 DOI: 10.3390/ijms22158149] [Reference Citation Analysis]
6 Zhu X, Na X, Zeng Y, Xu Y, Chai D, Yang H, Miao J, Zhang Y, Yang F, Wang Y, Zhou Y. Polyphyllin I combined with doxorubicin shows chemosensitization effect in vivo and reduces immunotoxicity of doxorubicin. Mol Cell Toxicol . [DOI: 10.1007/s13273-021-00206-w] [Reference Citation Analysis]
7 Xing H, Gao M, Wang Y, Zhang X, Shi J, Wang X, Liu X, Ma Q, Kong X, Yang C, Ding J, Meng L. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma. Clin Transl Med 2022;12:e835. [PMID: 35604910 DOI: 10.1002/ctm2.835] [Reference Citation Analysis]
8 Cai T, Zhou J, Zeng Y, Du W, Zhang Y, Liu T, Fu Y, Huang JA, Qian Q, Zhu J, Ling C, Liu Z. EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells. J Exp Clin Cancer Res 2020;39:84. [PMID: 32393392 DOI: 10.1186/s13046-020-01585-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X, Ding J, Meng LH. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism. J Immunother Cancer 2021;9:e003093. [PMID: 34373258 DOI: 10.1136/jitc-2021-003093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wang Y, Li X, Liu X, Chen Y, Yang C, Tan C, Wang B, Sun Y, Zhang X, Gao Y, Ding J, Meng L. Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer. Cancer Biol Med 2019;16:836. [PMID: 31908900 DOI: 10.20892/j.issn.2095-3941.2019.0401] [Reference Citation Analysis]
11 Yang Q, Ma X, Xiao Y, Zhang T, Yang L, Yang S, Liang M, Wang S, Wu Z, Xu Z, Sun Z. Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]